

Sri Krishna Pharmaceuticals Limited

NOTICE

Notice is hereby given that the **46th ANNUAL GENERAL MEETING** of the members of **SRI KRISHNA PHARMACEUTICALS LIMITED** will be held on Saturday, 31st July, 2021 at 10.30 A.M. at Uppal Industries Association Hall, Industrial Area, Uppal, Hyderabad - 500 039 to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Financial statements of the Company as at 31st March, 2021 and the Report of Board and the Auditors thereon.
2. To appoint a Director in place of Mr. V. V. Krishna Reddy (DIN: 00024216) who retires by rotation and being eligible, offers himself for re-appointment.
3. To appoint a Director in place of Dr. V. V. Subba Reddy (DIN: 00626671) who retires by rotation and being eligible, offers himself for re-appointment.
4. To declare Dividend.

SPECIAL BUSINESS:

5. To approve the remuneration payable to the cost auditor of the company for the financial year 2021-22.

To consider and if, thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Sec. 148 and all other applicable provisions of the Companies Act, 2013 read with the rules made there under and other applicable provisions if any of the Companies Act, 2013, including any statutory modifications or re-enactments thereof, the consent of the members be and is here by accorded to pay a remuneration of Rs.100,000/- per annum plus out of pocket expenses to Mr. N. V. S. Kapardi, Cost Accountant, the Cost Auditor of the Company for conducting the Audit of the cost records of the Company for the financial year 2021-22.”

Sri Krishna Pharmaceuticals Limited

6. Revision of remuneration of Dr. V. V. Subba Reddy, Whole Time Director (DIN: 00626671) of the Company.

To consider and if, thought fit to pass with or without modification(s), the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Sec. 197, 198 and 203 and all other applicable provisions, if any of the Companies Act, 2013 read with the Schedule V and the rules made thereunder, including any statutory modifications or re-enactments thereof, the approval of the members, be and is hereby accorded for revising the remuneration payable to Dr. V. V. Subba Reddy, Whole Time Director (DIN: 00626671) of the Company from Rs. 4,00,000/- to Rs.4,40,000/- per month w.e.f 01st August, 2021.

RESOLVED FURTHER THAT the remuneration payable to Dr. V. V. Subba Reddy, Whole Time Director (DIN: 00626671) of the Company shall also be the minimum remuneration payable in the event of loss or any inadequacy of profits in any particular financial year during his tenure.”

7. Revision of remuneration of Mr. V. V. Krishna Reddy, Managing Director (DIN:00024216) of the Company.

To consider and if, thought fit to pass with or without modification(s), the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Sec. 197, 198 and 203 and all other applicable provisions, if any of the Companies Act, 2013 read with the Schedule V and the rules made thereunder, including any statutory modifications or re-enactments thereof, the approval of the members be and is hereby accorded for revising the remuneration payable to Mr. V. V. Krishna Reddy, Managing Director (DIN: 00024216) of the Company from Rs. 3,50,000/- to Rs.3,85,000/- per month w.e.f 01st August, 2021.

RESOLVED FURTHER THAT the remuneration payable to Mr. V. V. Krishna Reddy, Managing Director (DIN: 00024216) of the Company shall also be the minimum remuneration payable in the event of loss or any inadequacy of profits in any particular financial year during his tenure.”

Sri Krishna Pharmaceuticals Limited

8. Approval of financial assistance to other entities.

To consider and if, thought fit to pass with or without modification(s), the following resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Section 185 and other applicable provisions, if any, of the Companies Act, 2013 (the “Act”) and the Companies (Meeting of Board and its Powers) Rules, 2014 (including any statutory modification(s), clarification(s), substitution(s) or re-enactment(s) thereof for the time being in force), consent of the Members of the Company, be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the “Board”, which term shall be deemed to include, unless the context otherwise required, any Committee of the Board or any Director(s) or Officer(s) authorised by the Board to exercise the powers conferred on the Board under this resolution) for giving loan(s) in one or more tranches including loan represented by way of book debt (the “Loan”) to, and/or giving of Corporate guarantee(s), and/or providing of security(ies) in connection with any Loan taken/to be taken by any entity which is a Subsidiary or Associate or Joint Venture or group entity of the Company or any other person in which any of the Director of the Company is deemed to be interested (collectively referred to as the “Entities”), up to a sum not exceeding Rs.150,00,00,000/- (Rupees one hundred and fifty crores Only) at any point in time, in its absolute discretion and in the best interest of the Company.

RESOLVED FURTHER THAT the powers be delegated to the Board of the Company and the Board is hereby authorised to negotiate, finalize, agree the terms and conditions of the aforesaid loan/corporate guarantee/security and to do all such acts, deeds and things as may be necessary and incidental including signing and/or execution of any deeds, documents, undertakings, agreements, papers, writings for giving effect to above Resolution.”

9. To amend the object clause of the Memorandum of Association of the Company.

To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to provisions of Section 13, Section 4 and other applicable provisions, if any, of the Companies Act, 2013, (“Act”) including any statutory modifications or re-enactment thereof for the time being in force and rules made thereunder and subject to such other requisite approvals, if any, in this regard from appropriate authorities and terms(s), condition(s), amendment(s), modification(s), as may be required or suggested by any such appropriate authorities, the consent of the members of the Company be and is

Sri Krishna Pharmaceuticals Limited

hereby accorded for replacing and amending the Main Object No. 3, 4 and 5 respectively in the Object Clause 3 (a) of the Memorandum of Association of the Company with the following objects:

Amended Objects No.3, 4 and 5 of Clause 3 (a) of the Main Objects of the Company:

3. To carry on business of Manufacturers of and dealers in all types of vegetables extracts, essential and mineral oils and oleoresins, fermentation products like food and fodder yeast, citric acid, alcohol and its allied and constituent products, enzymes and such other products in India and elsewhere.
4. To conduct research, development, in all kinds of bulk drugs, pharmaceuticals of every description, and / or demonstrate, application, biotechnological and biochemical processes and perform contract research in order to contribute to innovative process technology development & Research on various pharmaceutical and other related products and to put in continuous efforts in discovering and developing new molecules as drugs in pharmaceutical, biotech, healthcare, agriculture, marine and industrial sectors, including development of products and applications in Anti-microbial screening, Clinical pharmacology, recombinant DNA products, genetic engineering products, healthcare products, herb and herbal related products, Ayurvedic and Unani products, therapeutics, diagnostic kits, vaccines, medicinal plants and extracts and active ingredients, industrial enzymes, biotech and medicinal formulations, nutrients, biopesticides, bioinsecticides, enzymes, animal feeds, and biopolymers as well as bioinformatics, genomics and proteomics and to create and license technology / intellectual property rights for development of processes, products and services.
5. To access, process, trade and transfer technology in the field of Life Sciences, Tissue Culture, Molecular Biology, Agro and Immuno Technology, Bioinformatics, Genomics, Proteomics, R & D, both basic and applied research as well as contract development in the above relevant fields and to distribute, market, sell or assign the intellectual property rights or the technology in respect of the products or processes or patented process, of the pharmaceuticals of every description, biotechnological and biochemical processes developed to any other individual, firm, body corporate for a lump sum payment, royalty, technical fees, know-how fees or any other fee.

Clause III (B) of the Objects Clause of the Memorandum of Association of the Company be titled as "MATTERS WHICH ARE NECESSARY FOR FURTHERANCE OF THE OBJECTS SPECIFIED IN CLAUSE 3(A) ARE"

RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, the Board of Directors, be and is hereby authorized to do all such acts, deeds, matters and things as it may in its absolute discretion deem necessary, proper or desirable and to settle any questions, difficulties or doubts that may arise in this regard and to finalize and execute all documents and writings as may be necessary, proper, desirable or expedient as it may deem fit.”

10. To adopt Memorandum of Association of the Company as per the provisions of the Companies Act, 2013.

To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution**:

RESOLVED THAT pursuant to the provisions of Section 4, 13 and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”), read with the Companies (Incorporation) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force) and in accordance with the Table A of the Schedule I of the Act, consent of the members be and is hereby accorded for alteration in the Memorandum of Association of the Company, by merging appropriate and relevant objects of the Memorandum of Association, mentioned under Clause III (C) - ‘Other Objects’ with Clause 3 (b) - ‘Objects Incidental or Ancillary to the attainment of the Main Objects’ to appear under new Clause 3 (b) - ‘Matters which are necessary for furtherance of the objects specified in Clause 3 (a) are and consequently changing the object numbering as may be appropriate.

RESOLVED FURTHER THAT in accordance with the Table A of the Schedule I of the Act, the Clause 3 (b) of the Memorandum of Association of the Company, be renamed as under:

Clause 3 (b) - MATTERS WHICH ARE NECESSARY FOR FURTHERANCE OF THE OBJECTS SPECIFIED IN CLAUSE 3 (a) are:

RESOLVED FURTHER THAT necessary revision in numbering the clauses of the Memorandum of Association shall be carried out and adopt new set of the Memorandum of Association of the Company in accordance with the Schedule I of the Companies Act, 2013.

RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, the Board of Directors or Company Secretary of the company, be and is hereby authorized to do all such acts, deeds, matters and things as it may in its absolute discretion deem necessary, proper or desirable and to settle any questions, difficulties or doubts that may arise in this regard and to finalize and execute all documents and writings as may be necessary, proper, desirable or expedient as it may deem fit.”

Sri Krishna Pharmaceuticals Limited

11. To adopt new set of Articles of Association of the Company.

To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of section 14 of the Companies Act, 2013, and other applicable provisions read with the rules and regulations made there under including any amendment, re-enactment or statutory modification thereof, the new set of Articles of Association (as circulated along with notice of this meeting) be and are hereby approved and adopted in substitution for, and to the exclusion, of the existing Articles of Association of the Company.

RESOLVED FURTHER THAT any Director or Company Secretary of the company be and are hereby severally authorized to settle any question, difficulty or doubt, that may arise in giving effect to this resolution and to do all such acts, deeds, matters and things, including delegate such authority, as may be considered necessary, proper or expedient in order to give effect to the above resolution.

BY ORDER OF THE BOARD

Sd/-

KATERSALA JANARDHAN
COMPANY SECRETARY

Place: Hyderabad

Date: 10/05/2021

Sri Krishna Pharmaceuticals Limited

NOTES:

1. A MEMBER ENTITLED TO ATTEND AND TO VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF AND SUCH A PROXY NEED NOT BE A MEMBER OF THE COMPANY.
2. Proxy forms in order to be effective must be received at the Company's Registered Office not less than 48 hours before the meeting.
3. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights.
4. A member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.
5. The relevant Explanatory Statement, pursuant to Section 102 of the Companies Act, 2013 in respect of the Special Business set out above is annexed hereto.
6. The Register of Members and Share Transfer Books of the Company will remain closed from 28th July, 2021 to 31st July, 2021 (**both days inclusive**) for the purpose of Annual General Meeting.
7. Member/Proxy holder must bring the attendance slip to the meeting and hand it over at the entrance duly signed.
8. The Annual Report for the financial year 2020-21 has been sent through email to those members who have opted to receive electronic communication or who have registered their email addresses with the Company. The physical copy of the annual report has been sent to those members who have either opted for the same or have not registered their email addresses with the Company. The members who have not received the same may send a request to the Company.
9. Pursuant to the provisions of Section 124 and 125 of the Companies Act, 2013, an amount of Rs. 35,223/- was transferred by the Company to the Investor Education and Protection Fund ("IEPF") established by the Central Government. Pursuant to the provisions of Investor Education and Protection Fund (Uploading of Information regarding unpaid and unclaimed amounts lying with Companies) Rules, 2012, the Company has uploaded the details of

Sri Krishna Pharmaceuticals Limited

unpaid and unclaimed amounts lying with the Company as on 17.12.2020 on the website of the IEPF (www.iepf.gov.in) and also on the website of the Company (www.srikrishnapharma.com). Information in respect of unclaimed dividend pursuant to the provisions of Section 124 of the Companies Act, 2013 (corresponding provisions of Section 205A of the Companies Act, 1956), and the dates by which they need to be transferred is given below:

Financial year	Date of declaration	Due date for transfer to IEPF
2013-14	22/09/2014	28/10/2021
2014-15	31/07/2015	05/09/2022
2015-16	03/03/2016	08/04/2023
2016-17	31/07/2017	05/09/2024
2017-18	31/07/2018	05/09/2025
2019-20	10/08/2020	11/09/2027

Members should write to the Company if they have not encashed the dividend warrants so far in respect of the aforesaid financial year(s), well in advance of the above due dates.

- Members may note that shares as well as unclaimed dividends transferred to IEPF Authority can be claimed back from them. Concerned members/investors are advised to visit the weblink: <http://iepf.gov.in/IEPFA/refund.html>. for lodging claim for refund of shares and/or dividend from the IEPF Authority.

Sri Krishna Pharmaceuticals Limited

Statement Pursuant to Section 102 of the Companies Act, 2013

ITEM NO.5:

The Company is directed, under Section 148 of the Act to have the audit of its cost records conducted by a cost accountant in practice. The Board has on the recommendation of the Audit Committee, approved the appointment of Mr. N. V. S. Kapardi, Cost Accountant as the Cost Auditor of the Company to conduct Cost Audit relating to businesses of the Company as may be ordered by the Central Government under the Act and the Rules thereunder for the financial year 2021-22, at a remuneration of Rs.100,000 /- per annum plus out-of-pocket expenses.

Mr. N. V. S. Kapardi has vast experience in the field of cost audit and has conducted the audit of the cost records of the Company for the past several years.

In accordance with the provisions of Section 148 of the Act read with the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors has to be approved by the shareholders of the Company. Accordingly, consent of the members is sought for passing an Ordinary Resolution as set out at Item No. 5 of the Notice for ratification of the remuneration payable to the Cost Auditors for the financial year 2021-22.

None of the Directors / Key Managerial Personnel /Managers of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in this resolution.

The Board recommends the resolution for your approval.

ITEM NO.6 & 7:

Pursuant to Section 196, 197, 203 and in accordance with the recommendations of the Nomination and Remuneration Committee, read with schedule V and other applicable provisions, if, any of the Companies Act, 2013 Board of Directors of the Company proposes the revision in the remuneration of Dr. V.V. Subba Reddy (DIN: 00626671) Whole Time Director and Mr. V.V. Krishna Reddy (DIN: 00024216) Managing Director with effect from 1st August, 2021, subject to the approval of members of the company.

Sri Krishna Pharmaceuticals Limited

INFORMATION PURSUANT TO SCHEDULE V OF THE COMPANIES ACT, 2013

I. General Information:

- (1) **Nature of industry:** Our Company is active in the business of Pharmaceutical Raw materials (API's); Directly compressible granules, Vitamins, & Nutraceuticals.
- (2) **Date of commencement of commercial production:** The Company has commenced its business from 1975.
- (3) **Financial performance:**
(As per the latest audited accounts on 31st March, 2021)

Particulars	Rs. in lakhs
Profit/ (Loss) before tax	6760.85
Less: Current Tax	1831.57
Deferred Tax	250.33
Profit/ (Loss) after Tax	5179.61

II. Information about the Directors for whom revision in remuneration proposed:

(1) **Background details:**

Name	V.V. Subba Reddy	V.V. Krishna Reddy
Date of Birth	26-09-1942	31-08-1966
Educational qualification	M.Sc., (Tech.); Ph.D.	Chemical Engineer

(2) **Past remuneration:**

Name	V.V. Subba Reddy	V.V. Krishna Reddy
Monthly Remuneration	4,00,000/-	3,50,000/-

(3) **Recognition or awards:** Nil

(4) **Job profile:** Responsible for the functions of overall supervision of the Company

(5) **Remuneration proposed:**

Name	V.V. Subba Reddy	V.V. Krishna Reddy
Monthly Remuneration	4,40,000/-	3,85,000/-

Sri Krishna Pharmaceuticals Limited

- (6) **Comparative remuneration profile with respect to industry, size of the company, profile of the position and person:** The Board felt that the remuneration proposed is on lower side while considering the industry standards and his experience.
- (7) **Pecuniary relationship directly or indirectly with the company, or relationship with the managerial personnel, if any:** Mrs. V. Satyavathi, Director of the Company is the wife of the Chairman Dr. V. V. Subba Reddy and mother of Mr. V. V. Krishna Reddy, Managing Director.

The number of shares held by the Directors in the Company is as follows:

Dr. V. V. Subba Reddy: 19,14,433

Mr. V.V. Krishna Reddy: 23,38,771

Save and except the above, said Director and their relatives, to the extent of their shareholding interest, if any, in the Company, none of the other Directors / Key Managerial Personnel/ Managers of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in this resolution.

The Board recommends the resolutions for your approval.

ITEM NO.8:

The Company may have to render support for the business requirements of its Subsidiary Companies or Associate or Joint Venture or group entity or any other person in whom any of the Director of the Company is deemed to be interested (collectively referred to as the "Entities"), from time to time. However, owing to certain restrictive provisions contained in Section 185 of the Companies Act, 2013 ('the Act'), the Company was unable to extend financial assistance by way of loan or providing guarantees to such Entities.

The Board of Directors seek consent of the Members by way of a Special Resolution pursuant to Section 185 of the Act (as amended from time to time) for making loan(s) or providing financial assistance or providing guarantee or securities in connection with the loans taken or to be taken by the Entities for the capital expenditure of the projects and/or working capital requirements including purchase of fixed assets as may be required from time to time for the expansion of its business activities and other matters connected and incidental thereon for their principal business activities.

Sri Krishna Pharmaceuticals Limited

The Members may note that Board of Directors would carefully evaluate proposals and provide such loan, guarantee or security through deployment of funds out of internal resources/accruals and/or any other appropriate sources, from time to time, only for principal business activities of such Entities.

Save and except Dr. V.V. Subba Reddy, Mr. V.V. Krishna Reddy, Directors and their Relatives, to the extent of their Shareholding interest, if any, in the company none of the Directos (or) Key managerial personnel / Managers of the company / their relatives are, in any way, concerned (or) interested, financially (or) otherwise, in this resolution.

ITEM NO. 9&10:

Considering the business expansion opportunities identified from time to time and in order to carry out activities, the object clause of the Memorandum of Association of the Company needs amendment to include, amend and replace the main objects of the Company by amendment to Clause 3 (a) of the Memorandum of Association of the Company.

Upon enactment of the Companies Act, 2013, the Memorandum of Association of the Company was required to be re-aligned as per the provisions of the Companies Act, 2013.

The draft of the amended Memorandum of Association proposed for approval, are circulated along with this notice and also available for inspection by the shareholders of the Company during normal business hours at the Registered office of the Company and copies thereof shall also be made available for inspection at the Corporate Office of the Company and also at the place of the meeting on the meeting day.

In terms of Section 4 and 13 of the Companies Act, 2013, the consent of the Members by way of Special Resolution is required for approval of proposed amendments in the Memorandum of Association of the Company.

Your Directors recommend passing of this resolution by way of a special resolution.

None of the directors, KMPs, or their relatives are interested or concerned, financially or otherwise, in the resolution set out at item no. 9 & 10.

ITEM NO. 11:

Upon enactment of the Companies Act, 2013, various provisions of the Companies Act, 1956 have been repealed and in view of the same the Articles of Association of the Company needs to be re-aligned as per the provisions of the Companies act, 2013 and it is proposed to adopt a new

Sri Krishna Pharmaceuticals Limited

set of Articles of Association in place of and to the exclusion of existing Articles of Association of the Company.

The draft of the new set of Articles proposed for approval is being circulated along with this notice of the Annual General Meeting and also available for inspection by the shareholders of the Company during normal business hours at the Registered office of the Company and copies thereof shall also be made available for inspection at the Corporate Office of the Company and also at the place of the meeting on the meeting day.

In terms of Section 14 of the Companies Act, 2013, the consent of the Members by way of special resolution is required for adoption of new set of Articles of Association of the Company.

Your Directors recommend passing of this resolution by way of a special resolution.

None of the directors, KMPs, or their relatives are interested or concerned, financially or otherwise, in the resolution set out at item no. 11.

BY ORDER OF THE BOARD

Sd/-

KATERSALA JANARDHAN
COMPANY SECRETARY

Place: Hyderabad

Date: 10/05/2021

Sri Krishna Pharmaceuticals Limited

SRI KRISHNA PHARAMACEUTICALS LIMITED

Registered Office: C-4, Industrial Area, Uppal, Hyderabad, Telangana - 500 039.

CIN: U24230TG1974PLC001790

Admission slip

Folio No./DP ID & Client ID.....

No. of Shares Id.....

I declare that I am a registered Shareholder of the Company

(Member's Signature)

I hereby record my presence at the **46th Annual General Meeting of the Company** being held at Uppal Industries Association Hall, Industrial Area, Uppal, Hyderabad - 500 039 **on Saturday, 31st July, 2021 at 10.30 a.m.** as member / as a Proxy appointed by _____

(Signature of Member / Proxy)

- NOTE:**
1. A member/Proxy attending the meeting must complete this admission slip and hand it over at the entrance.
 2. Member intending to appoint a Proxy, should complete the Proxy form below and deposit at the Company's Registered Office not less than 48 hours before the commencement of the meeting.

Sri Krishna Pharmaceuticals Limited

SRI KRISHNA PHARAMACEUTICALS LIMITED

Registered Office: C-4, Industrial Area, Uppal, Hyderabad, Telangana - 500 039.

CIN: U24230TG1974PLC001790

PROXY FORM

Name of the member(s) :
Registered Address :
E-Mail ID :
Folio No/ Client ID :
DP ID :

I/We, being the member(s) of _____ shares of the above named company, hereby appoint

1. Name :
Address :
E-mail Id :
Signature : , or failing him
2. Name :
Address :
E-mail Id :
Signature : , or failing him
3. Name :
Address :
E-mail Id :
Signature :

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 46th Annual General Meeting of the company, to be held on Saturday, 31st July, 2021 at 10.30 A.M at Uppal Industries Association Hall, Industrial Area, Uppal, Hyderabad - 500039 and at any adjournment thereof in respect of such resolutions as are indicated below:

SL. NO	RESOLUTIONS
1	To receive, consider and adopt the Financial statements of the Company as at 31 st March, 2021 and the Report of Board and the Auditors thereon
2	To appoint a Director in place of Mr. V. V. Krishna Reddy (DIN: 00024216) who retires by rotation and being eligible, offers himself for re-appointment
3	To appoint a Director in place of Dr. V. V. Subba Reddy (DIN: 00626671) who retires by rotation and being eligible, offers himself for re-appointment
4	To declare Dividend
5	To approve the remuneration payable to the Cost Auditor of the company for the financial year 2021-22
6	Revision of remuneration of Dr. V. V. Subba Reddy, Whole Time Director (DIN: 00626671) of the Company
7	Revision of remuneration of Mr. V. V. Krishna Reddy, Managing Director (DIN: 00024216) of the Company
8	Approval of financial assistance to other entities
9	To amend the object clause of the Memorandum of Association of the Company
10	To adopt Memorandum of Association of the Company as per the provisions of the Companies Act, 2013
11	To adopt new set of Articles of Association of the Company

Signed this _____ day of _____ 2021

Signature of shareholder

Signature of Proxy holder(s)

Affix
Revenue
Stamp

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

Sri Krishna Pharmaceuticals Limited

